Winslow Evans & Crocker’s Myriad Genetics MYGN Stock Holding History

Winslow Evans & Crocker’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-226	Closed	-$8K	–	1273
2019 Q1	$8K	Buy	226 +70	+45%	+$2.13K	﹤0.01%	874
2018 Q4	$6K	Buy	156 +126	+420%	+$4.53K	﹤0.01%	885
2018 Q3	$2K	Hold	30	–	–	﹤0.01%	1046
2018 Q2	$2K	Hold	30	–	–	﹤0.01%	1055
2018 Q1	$888	Hold	30	–	–	﹤0.01%	1073
2017 Q4	$1.03K	Buy	+30	New	+$1.01K	﹤0.01%	1067

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Winslow Evans & Crocker's MYGN Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 226 shares — an estimated $8K sold.

Winslow Evans & Crocker first reported a position in MYGN in Q4 2017 and held it in 6 quarters. The position peaked at $8K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Winslow Evans & Crocker reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Winslow Evans & Crocker sold 226 Myriad Genetics shares in Q2 2019, an estimated $8K.
Winslow Evans & Crocker first reported a position in Myriad Genetics in Q4 2017 and held it in 6 quarters.
Winslow Evans & Crocker's Myriad Genetics position peaked at $8K in Q1 2019.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.